Montagnino G, Tarantino A, Banfi G, Maccario M, Costamagna L, Ponticelli C
Divisione di Nefrologia e Dialisi, Ospedale Maggiore IRCCS, Milan, Italy.
Transpl Int. 2000;13(2):166-8. doi: 10.1007/s001470050316.
A patient who had undergone a first cadaveric donor kidney transplantation for idiopathic focal segmental glomerular sclerosis (FSGS), had an immediate recurrence of a biopsy-proven FSGS that eventually led to graft failure within 5 years from transplantation. The patient underwent a second cadaveric transplantation 10 months later. An immediate recurrence of a biopsy-proven FSGS occurred that was treated with two protracted cycles of plasmapheresis of seven months each, with the addition of an ACE inhibitor from the beginning. A complete and stable remission of FSGS was observed, which continues after more than 6 years from the end of plasmapheresis. The recurrence of FSGS after a second transplantation has a poor prognosis, but prolonged plasmapheresis treatment, by removing circulating factors altering glomerular permselectivity, and the addition of ACE inhibitors, through their potential interference with TGF-beta, might be synergistic in obtaining permanent remission.
一名因特发性局灶节段性肾小球硬化症(FSGS)接受首次尸体供肾移植的患者,移植后经活检证实FSGS立即复发,最终在移植后5年内导致移植肾失功。该患者在10个月后接受了第二次尸体肾移植。移植后经活检证实FSGS再次立即复发,采用了两个疗程长达7个月的血浆置换治疗,且从一开始就加用了一种血管紧张素转换酶抑制剂(ACE抑制剂)。观察到FSGS完全且稳定缓解,血浆置换结束6年多后仍持续缓解。第二次移植后FSGS复发预后较差,但延长血浆置换治疗,通过清除改变肾小球滤过屏障的循环因子,以及加用ACE抑制剂,通过其对转化生长因子-β(TGF-β)的潜在干扰作用,可能在获得永久性缓解方面具有协同作用。